All Updates

All Updates

icon
Filter
Funding
Tachyon Therapeutics raises USD 11.6 million for clinical study
Precision Medicine
Mar 1, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Mar 1, 2023

Tachyon Therapeutics raises USD 11.6 million for clinical study

Funding

  • Tachyon Therapeutics, a clinical-stage biotechnology company, raised USD 11.6 million via an equity funding round, with the investors including Veblen Ventures, Khosla Ventures, Red Tree Venture Capital, and other existing investors. This brings the total funds raised to USD 18.7 million, including USD 7.1 million in grant funding. 

  • The new funds will be used to conduct phase 1 clinical trials of TACH 101, a small molecule KDM4 histone demethylase inhibitor, for advanced solid tumors. In addition, the funds will be used to progress the company’s lineup of novel oncology drugs, candidates which are aimed at previously unexamined mechanisms of tumor formation. 

  • California-based Tachyon Therapeutics is a biotechnology company focused on developing small-molecule drugs for the treatment of cancer. The company’s research is centered on identifying and targeting novel mechanisms of tumorigenesis, which are the processes that lead to the formation and growth of tumors. The company’s lead drug candidate, TACH 101, is a first-class KDM4 histone demethylase inhibitor that is currently undergoing clinical trials for the treatment of advanced solid tumors.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.